PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2012 | 7 | 4 | 429-434
Tytuł artykułu

Alendronate in patients with calcium nephrolithiasis and loss of bone mass

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Słowa kluczowe
Wydawca

Czasopismo
Rocznik
Tom
7
Numer
4
Strony
429-434
Opis fizyczny
Daty
wydano
2012-08-01
online
2012-05-24
Twórcy
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain, arrabalp@ono.com
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain
  • Medicine Department, Granada University, 18003, Granada, Spain
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain
Bibliografia
  • [1] Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Study of the physical-chemical factors in patients with renal lithiasis. Arch Esp Urol. 2006; 59:583–594
  • [2] Arrabal Martín M, Díaz de la Guardia FV, Jiménez Pacheco A, López León V, Arrabal Polo MA, Zuluaga Gómez A. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol. 2007; 60:745–754 http://dx.doi.org/10.4321/S0004-06142007000700004[Crossref]
  • [3] Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009; 41:926–930 http://dx.doi.org/10.1038/ng.404[WoS][Crossref]
  • [4] Cipriani Thorne E. Osteoporosis: Consideraciones diagnosticas y terapeuticas. Rev Med Hered. 2004; 15:101–107
  • [5] Moro-Alvarez MJ, Cabrera JA. Osteoporosis in men. Rev Clin Esp. 2010; 210:342–349 http://dx.doi.org/10.1016/j.rce.2009.11.023[Crossref]
  • [6] Morales Piga A. Advances in the treatment of osteoporosis at the beginning of the new millennium. Rev Clin Esp. 2002; 202:23–26 [Crossref][PubMed]
  • [7] Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95:1555–1565 http://dx.doi.org/10.1210/jc.2009-1947[Crossref]
  • [8] Adrover Rigo M, Juste Diez de Pinos JL, Tuset Creus M, Codina Jane C, Ribas Sala J. Revision clínica de la utilización de los bifosfonatos. Farm Hosp. 2000; 24:74–82
  • [9] Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull. 2002; 49:1–18 [PubMed]
  • [10] Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007; 23:1341–1349 http://dx.doi.org/10.1185/030079907X188035[WoS][Crossref]
  • [11] Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24:237–244 [Crossref]
  • [12] Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116–1125 http://dx.doi.org/10.1210/jc.86.3.1116[Crossref]
  • [13] Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29:1548–1558 http://dx.doi.org/10.1016/j.clinthera.2007.08.008[WoS][Crossref]
  • [14] Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010; 22:404–409 http://dx.doi.org/10.1097/BOR.0b013e32833ad677[WoS][Crossref]
  • [15] Venkatanarasimha N, Miles G, Suresh P. Subtrochanteric femoral insufficiency fractures related to the use of long-term biphosphonates: a pictorial review. Emerg Radiol. 2010; 17:511–515 http://dx.doi.org/10.1007/s10140-010-0890-y[Crossref]
  • [16] Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95:5258–5265 http://dx.doi.org/10.1210/jc.2010-1571[Crossref][WoS]
  • [17] Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García-Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006; 68:956–959 http://dx.doi.org/10.1016/j.urology.2006.06.007[Crossref]
  • [18] Sakhaee K, Maalouf N, Kumar R, Pasch A, Moe O. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011; 79:393–403 http://dx.doi.org/10.1038/ki.2010.473[WoS][Crossref]
  • [19] Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine. 2004; 71:51–55 http://dx.doi.org/10.1016/j.jbspin.2003.09.009[Crossref]
  • [20] Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999; 55:234–243 http://dx.doi.org/10.1046/j.1523-1755.1999.00247.x[Crossref]
  • [21] Ruml LA, Dubois SK, Roberts ML, Pak CY. Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res. 1995; 10:655–662 http://dx.doi.org/10.1002/jbmr.5650100420[Crossref]
  • [22] Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int. 2007; 71:808–815 http://dx.doi.org/10.1038/sj.ki.5002181[WoS][Crossref]
  • [23] Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009; 24:1472–1477 http://dx.doi.org/10.1093/ndt/gfn690[Crossref]
  • [24] Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol. 2002; 168:937–940 http://dx.doi.org/10.1016/S0022-5347(05)64546-6[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-012-0014-z
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.